SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

1,270

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Tiotropium bromide 18mcg

DRUG

Fluticasone propionate/ salmeterol combination 50/500mcg

Trial Locations (166)

855

GSK Investigational Site, Oslo

1000

GSK Investigational Site, Brussels

1020

GSK Investigational Site, Brussels

1150

GSK Investigational Site, Oslo

1162

GSK Investigational Site, Tallinn

1270

GSK Investigational Site, Litija

1606

GSK Investigational Site, Fredrikstad

2311

GSK Investigational Site, Zgornje Hoče

2391

GSK Investigational Site, Moelv

2400

GSK Investigational Site, København NV

2650

GSK Investigational Site, Edegem

2700

GSK Investigational Site, Deva

3000

GSK Investigational Site, Leuven

3326

GSK Investigational Site, Topolšica

3600

GSK Investigational Site, Genk

3680

GSK Investigational Site, Kiev

4000

GSK Investigational Site, Liège

4204

GSK Investigational Site, Golnik

5053

GSK Investigational Site, Bergen

6100

GSK Investigational Site, Volda

9000

GSK Investigational Site, Ghent

10178

GSK Investigational Site, Berlin

10367

GSK Investigational Site, Berlin

10559

GSK Investigational Site, Berlin

10585

GSK Investigational Site, Berlin

10965

GSK Investigational Site, Berlin

13619

GSK Investigational Site, Tallinn

15669

GSK Investigational Site, Athens

16132

GSK Investigational Site, Genoa

20099

GSK Investigational Site, Sesto San Giovanni (MI)

20132

GSK Investigational Site, Milan

20142

GSK Investigational Site, Milan

26026

GSK Investigational Site, Rivolta d'Adda (CR)

28041

GSK Investigational Site, Madrid

28047

GSK Investigational Site, Madrid

28500

GSK Investigational Site, Vic

33602

GSK Investigational Site, Bielefeld

34117

GSK Investigational Site, Kassel

34121

GSK Investigational Site, Kassel

35037

GSK Investigational Site, Marburg

35128

GSK Investigational Site, Padua

37269

GSK Investigational Site, Eschwege

44100

GSK Investigational Site, Ferrara

48903

GSK Investigational Site, Barakaldo (Vizcaya)

48960

GSK Investigational Site, Galdakano

50009

GSK Investigational Site, Zaragoza

51014

GSK Investigational Site, Tartu

56124

GSK Investigational Site, Pisa

63100

GSK Investigational Site, Ascoli Piceno

63571

GSK Investigational Site, Gelnhausen

68100

GSK Investigational Site, Periohi Dragana, Alexandroupolis

69469

GSK Investigational Site, Weinheim

70000

GSK Investigational Site, Bucharest

70020

GSK Investigational Site, Cassano Murge (BA)

71100

GSK Investigational Site, Foggia

71409

GSK Investigational Site, Heraklion, Crete

72712

GSK Investigational Site, Paide

73300

GSK Investigational Site, Chania, Crete

74100

GSK Investigational Site, Rethymnon, Crete

80024

GSK Investigational Site, Pärnu

80131

GSK Investigational Site, Napoli

80335

GSK Investigational Site, Munich

81677

GSK Investigational Site, Munich

82037

GSK Investigational Site, Telese (BN)

83646

GSK Investigational Site, Bad Tölz

84025

GSK Investigational Site, Eboli (SA)

84126

GSK Investigational Site, Salerno

86156

GSK Investigational Site, Augsburg

86825

GSK Investigational Site, Bad Woerrishofen

91052

GSK Investigational Site, Erlangen

97688

GSK Investigational Site, Bad Kissingen

109240

GSK Investigational Site, Moscow

400371

GSK Investigational Site, Cluj-Napoca

664005

GSK Investigational Site, Irkutsk

700115

GSK Investigational Site, Iași

A-2840

GSK Investigational Site, Grimmenstein

A-2340

GSK Investigational Site, Mödling

A-5020

GSK Investigational Site, Salzburg

A-1120

GSK Investigational Site, Vienna

678 31

GSK Investigational Site, Blansko

697 33

GSK Investigational Site, Kyjov

775 25

GSK Investigational Site, Olomouc

703 00

GSK Investigational Site, Ostrava

301 00

GSK Investigational Site, Pilsen

326 00

GSK Investigational Site, Pilsen

140 46

GSK Investigational Site, Prague

180 81

GSK Investigational Site, Prague

DK-9100

GSK Investigational Site, Aalborg

DK-8000

GSK Investigational Site, Aarhus C

DK-5000

GSK Investigational Site, Odense C

Unknown

GSK Investigational Site, Tallinn

GSK Investigational Site, Kavala

GSK Investigational Site, Egsjordet

GSK Investigational Site, Alicante

GSK Investigational Site, Figueres

GSK Investigational Site, Orihuela (Alicante)

GSK Investigational Site, Kyiv

GSK Investigational Site

184 54

GSK Investigational Site, Athens

06132

GSK Investigational Site, San Sisto (PG)

LV 5201

GSK Investigational Site, Jēkabpils

LV 1002

GSK Investigational Site, Riga

LV 1035

GSK Investigational Site, Riga

LV1079

GSK Investigational Site, Riga

LT-62114

GSK Investigational Site, Alytus

LT-50009

GSK Investigational Site, Kaunas

LT-92231

GSK Investigational Site, Klaipėda

LT-92288

GSK Investigational Site, Klaipėda

LT-07156

GSK Investigational Site, Vilnius

5211 NL

GSK Investigational Site, 's-Hertogenbosch

7609 PP

GSK Investigational Site, Almelo

1315 RA

GSK Investigational Site, Almere Stad

3818 ES

GSK Investigational Site, Amersfoort

1034 CS

GSK Investigational Site, Amsterdam

1091 AC

GSK Investigational Site, Amsterdam

1105 AZ

GSK Investigational Site, Amsterdam

6815 AD

GSK Investigational Site, Arnhem

4819 EV

GSK Investigational Site, Breda

5623 EJ

GSK Investigational Site, Eindhoven

3844 DG

GSK Investigational Site, Harderwijk

1624 NP

GSK Investigational Site, Hoorn

2353 GA

GSK Investigational Site, Leiderdorp

7943 KA

GSK Investigational Site, Meppel

5342 BT

GSK Investigational Site, Oss

8601 ZK

GSK Investigational Site, Sneek

5504 DB

GSK Investigational Site, Veldhoven

5912 BL

GSK Investigational Site, Venlo

6001 BE

GSK Investigational Site, Weert

8025 AB

GSK Investigational Site, Zwolle

N-1346

GSK Investigational Site, Gjettum

N-7027

GSK Investigational Site, Trondheim

N-7030

GSK Investigational Site, Trondheim

N-3117

GSK Investigational Site, Tønsberg

020125

GSK Investigational Site, Bucharest

050159

GSK Investigational Site, Bucharest

105 077

GSK Investigational Site, Moscow

105 229

GSK Investigational Site, Moscow

119 881

GSK Investigational Site, Moscow

197 089

GSK Investigational Site, Saint Petersburg

085 01

GSK Investigational Site, Bardejov

811 01

GSK Investigational Site, Bratislava

833 40

GSK Investigational Site, Bratislava

040 01

GSK Investigational Site, Košice

971 01

GSK Investigational Site, Prievidza

08035

GSK Investigational Site, Barcelona

08221

GSK Investigational Site, Barcelona

SE-575 81

GSK Investigational Site, Eksjö

SE-651 85

GSK Investigational Site, Karlstad

SE-581 85

GSK Investigational Site, Linköping

SE-971 89

GSK Investigational Site, Luleå

SE-205 02

GSK Investigational Site, Malmo

SE-701 85

GSK Investigational Site, Örebro

SE-141 86

GSK Investigational Site, Stockholm

SE-171 76

GSK Investigational Site, Stockholm

SE-751 85

GSK Investigational Site, Uppsala

03680

GSK Investigational Site, Kiev

PE3 6DA

GSK Investigational Site, Peterborough

G4 0SF

GSK Investigational Site, Glasgow

L9 7AL

GSK Investigational Site, Liverpool

M8 5RB

GSK Investigational Site, Manchester

TW7 6AG

GSK Investigational Site, Isleworth

EH3 9YW

GSK Investigational Site, Edinburgh

NE1 4LP

GSK Investigational Site, Newcastle upon Tyne

NE7 7DN

GSK Investigational Site, Newcastle upon Tyne

B15 2TH

GSK Investigational Site, Birmingham

E2 9JX

GSK Investigational Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00361959 - SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter